A well-supplied UK & EU sector, led by PRINTING HOUSE LTD, most recent listing 11 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
This contract opportunity involves establishing non-exclusive discount agreements for the drug Safinamide (ATC Code: N04BD03) under Section 130a (8) of the German Social Code (SGB V). The agreements will be made through an Open House model, allowing all interested pharmaceutical companies to partici
This announcement is for the establishment of contracts to supply medical dressings to the insured members of AOK NW, in accordance with § 31 SGB V, through an Open-House procedure. All qualified and interested service providers are invited to enter into this contract under uniform contractual condi
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredient Nilotinib (ATC: L01EA03) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
The German Social Code allows health insurance funds and pharmaceutical companies to enter into framework discount agreements for medications covered by statutory health insurance. In accordance with the relevant legal provisions for public procurement, a regular process of substance-related formal
The Techniker Krankenkasse (TK) aims to establish discount contracts with all suitable pharmaceutical companies for the combination of active ingredients Beclometasone, Formoterol, and Glycopyrronium (ATC: R03AL09) under Section 130a (8) of the Social Code Book V. The contract will be concluded as p
The health insurance funds (whether HEK and/or hkk participate in the respective lot is determined by the designation of the respective lot) aim to enter into discount contracts with all suitable pharmaceutical companies according to § 130a Abs. 8 SGB V for the active ingredients, combinations of ac
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the pharmaceutical substances Dolutegravir and Rilpivirine, classified under ATC J05AR21. This agreement will be effective from July 1, 2025, to June 30, 2027. The contract is part of a framework that allows
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Epoetin Zeta, as permitted under Section 130a, Paragraph 8 of the German Social Code (SGB V). The GWQ ServicePlus AG, acting on behalf of health insurance companies, is seeking to
The DAK-Gesundheit is seeking suppliers to enter into a non-exclusive discount agreement for the drug Cyanocobalamin (ATC B03BA01) under the provisions of § 130a Abs. 8 SGB V. This agreement will be effective from July 1, 2025, to June 30, 2027, with an option to extend for an additional 12 months.
This contract opportunity involves establishing non-exclusive discount agreements for finished pharmaceuticals with various active ingredients or combinations of active ingredients under an 'Open-House Model' as per § 130a Abs. 8 SGB V. Suppliers can join or sign contracts at any time under the same
